Royalty Pharma plc (RPRX) 当前追踪市盈率 (P/E) 为 26.8, 前瞻市盈率为 10.0. 追踪盈利收益率为 3.73%, 前瞻盈利收益率 10.05%. PEG 1.11. 格雷厄姆数为 $30.06.
本页证实的标准:
SharesGrow 综合评分： 72/100 其中 5/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 47.7 | -15.27 | 6.08 | 14.39 | - |
| 2017 | 13.0 | 0.05 | 3.53 | 9.86 | 4.66% |
| 2018 | 11.4 | 0.83 | 3.51 | 8.78 | 5.17% |
| 2019 | 6.7 | 0.10 | 2.58 | 8.69 | 4.69% |
| 2020 | 19.9 | -0.25 | 4.03 | 9.15 | 2.05% |
| 2021 | 26.7 | 1.63 | 2.86 | 7.22 | 1.73% |
| 2022 | 404.1 | -4.33 | 3.08 | 7.74 | 1.93% |
| 2023 | 11.1 | 0.00 | 1.93 | 5.34 | 2.85% |
| 2024 | 13.2 | -0.31 | 1.64 | 5.03 | 3.31% |
| 2025 | 21.6 | 1.04 | 2.58 | 7.02 | 2.27% |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $0.93 | $1.88B | $565.91M | 30.1% |
| 2017 | $3.42 | $1.6B | $1.21B | 75.7% |
| 2018 | $3.89 | $1.79B | $1.38B | 76.8% |
| 2019 | $6.42 | $1.81B | $2.35B | 129.4% |
| 2020 | $1.32 | $2.12B | $495.2M | 23.3% |
| 2021 | $1.15 | $2.29B | $478.75M | 20.9% |
| 2022 | $0.10 | $2.24B | $42.83M | 1.9% |
| 2023 | $2.53 | $2.35B | $1.13B | 48.2% |
| 2024 | $1.45 | $2.26B | $859M | 37.9% |
| 2025 | $1.80 | $2.38B | $770.95M | 32.4% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $4.86 | $4.27 – $5.11 | $3.25B | $3.2B – $3.26B | 4 |
| 2027 | $5.25 | $4.58 – $5.78 | $3.48B | $3.45B – $3.51B | 4 |
| 2028 | $6.08 | $5.95 – $6.22 | $3.97B | $3.97B – $3.97B | 1 |
| 2029 | $7.04 | $6.89 – $7.19 | $4.59B | $4.51B – $4.66B | 1 |
| 2030 | $7.71 | $7.54 – $7.88 | $4.99B | $4.91B – $5.08B | 1 |
